reports
OPKO Health to Participate in the 3rd Annual Piper Sandler Virtual Obe...
OPKO Health to Participate in the 3rd Annual Piper Sandler Virtual Obesity Symposium MIAMI, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) today announced its participation in the 3rd Annual Piper Sandler Obesity Symposium being held virtually on June 26, 2025. Management will be participating in a fireside discussion moderated by Edward Tentoff, Managing Director, Senior Biotechnology Analyst. Investors can register for the symposium by contacting their Piper Sandler representative. About OPKO Health OPKO is a multinational biopharmaceutical and diagnostics ...
OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Gluc...
OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting MIAMI and JERUSALEM, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX) (“Entera”) today announced that new pharmacologic and pharmacokinetic in vivo data for investigational oral OPK-88006 tablet treatment has been selected for presentation at the ENDO 2025 annual meeting of the Endocrine Society, taking place July 12-15, 2025 in San Francisc...
OPKO Health’s ModeX Therapeutics Announces Formation of Scientific Adv...
OPKO Health’s ModeX Therapeutics Announces Formation of Scientific Advisory Board with Leaders at the Forefront of Immunology and Oncology Drug Development Will provide expertise across ModeX’s portfolio of next generation multispecific antibodies for complex diseases involving the immune system, including cancer ModeX’s promising immunology pipeline includes first-in class drugs with two assets in ongoing clinical trials and multiple pre-IND assets to enter clinical trials WESTON, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), to...
UFP Technologies to Present and Host 1x1 Investor Meetings at the 15th...
UFP Technologies to Present and Host 1x1 Investor Meetings at the 15th Annual East Coast IDEAS Investor Conference on June 11th in New York, NY NEWBURYPORT, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- UFP Technologies (UFPT), today announced Jeffrey Bailly, Chairman and CEO and Ron Lataille, Sr. Vice President & CFO, will present at the East Coast IDEAS Investor Conference on Wednesday, June 11, 2025 at The Westin Times Square in New York, NY. UFP’s presentation is scheduled to begin at 7:55 AM ET. The presentation is webcast and can be accessed through the conference host’s main website: a...
UFP Technologies, Inc. to Present and Host 1x1 Investor Meetings at th...
UFP Technologies, Inc. to Present and Host 1x1 Investor Meetings at the Goldman Sachs 46th Annual Global Healthcare Conference NEWBURYPORT, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (Nasdaq: UFPT), today announced that Jeffrey Bailly, Chairman and CEO, and Ron Lataille, Sr. Vice President & CFO, will present at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025. UFP’s fireside chat is scheduled to begin at 11:20 AM ET. About UFP Technologies, Inc. UFP Technologies is a designer and custom manufacturer of comprehensive solutions for m...
Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Ma...
Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040 ANN ARBOR, Mich., June 02, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Hetero USA, Inc. and its affiliates Hetero Labs Limited, Hetero Labs Limited Unit-V, and Honour Lab Limited (together, Hetero USA). This agreement resolves the patent litigation brought by Esperion against Hetero USA in response to Hetero USA’ s Abbreviated New Drug Application (ANDA) seeking approval to...
- Jonathan Moreland
SON SONOCO PRODUCTS COMPANY
NCR NCR CORPORATION
UNH UNITEDHEALTH GROUP INCORPORATED
RYAM RAYONIER ADVANCED MATERIALS INC
PLUG PLUG POWER INC.
PENN PENN NATIONAL GAMING INC.
PEB PEBBLEBROOK HOTEL TRUST
OEC ORION ENGINEERED CARBONS SA
MTX MINERALS TECHNOLOGIES INC.
MTDR MATADOR RESOURCES COMPANY
MO ALTRIA GROUP INC
LGND LIGAND PHARMACEUTICALS INCORPORATED
JRVR JAMES RIVER GROUP HOLDINGS LTD
HUN HUNTSMAN CORPORATION
HUM HUMANA INC.
ASB ASSOCIATED BANC-CORP
NEWT NEWTEK BUSINESS SERVICES INC.
RLMD RELMADA THERAPEUTICS
VFF VILLAGE FARMS INTERNATIONAL IN
HTLD HEARTLAND EXPRESS INC.
VSH VISHAY INTERTECHNOLOGY INC.
SWM SCHWEITZER-MAUDUIT INTERNATIONAL INC.
BXC BLUELINX HOLDINGS
GBLI GLOBAL INDEMNITY PLC
AMBC AMBAC FINANCIAL GROUP INC.
FCNCA FIRST CITIZENS BANCSHARES INC. CLASS A
CARS CARS.COM INC.
BRT BRT APARTMENTS
SNBR SLEEP NUMBER CORPORATION
MBIN MERCHANTS BANCORP
PMTS CPI CARD GROUP
LILA LIBERTY LATIN AMERICA A
COLD AMERICOLD REALTY TRUST
BBDC BARINGS BDC INC.
UTGN UTG
RPAY REPAY HOLDINGS (A)
XRX XEROX HOLDINGS CORPORATION
VLA ARBOR METALS
ONEW ONEWATER MARINE
MTCH MATCH GROUP INC.
PRG PROG HOLDINGS
MINM INC.
CIVI MINIM
UDMY INC.
OGN CIVITAS RESOURCES INC
OPAL UDEMY INC
PRME ORGANON & CO
VFC OPAL FUELS INC
PHIN PRIME MEDICINE INC
NCDL VF CORPORATION
FIP PHINIA INC
FG NUVEEN CHURCHILL DIRECT LENDING CORP
HCWB FTAI INFRASTRUCTURE INC
NEO F AND G ANNUITIES AND LIFE
INC.
HCW BIOLOGICS INC
NEO CORPORATE PUBLIC COMPANY LIMITED
Middlefield Banc Corp. Announces Retirement of Darryl E. Mast from Boa...
Middlefield Banc Corp. Announces Retirement of Darryl E. Mast from Board of Directors MIDDLEFIELD, Ohio, May 22, 2025 (GLOBE NEWSWIRE) -- Middlefield Banc Corp. (NASDAQ: MBCN) today announced the retirement of Darryl E. Mast from its Board of Directors, effective May 14, 2025. Mr. Mast joined the Middlefield Banking Company’s Board of Directors in 2011 and has been a Director of Middlefield Banc Corp. since 2013. His leadership, insight, and expertise have been integral to the success of Middlefield Banc Corp. and The Middlefield Banking Company, and his contributions have left a lasting...
- Jonathan Moreland
MMLP MARTIN MIDSTREAM PARTNERS L.P.
JRVR JAMES RIVER GROUP HOLDINGS LTD
NEWT NEWTEK BUSINESS SERVICES INC.
RLMD RELMADA THERAPEUTICS
BBDC BARINGS BDC INC.
ENR EDGEWELL PERSONAL CARE COMPANY
INZY INOZYME PHARMA
ALIT ALIGHT
WEST INC. / DELAWARE
STRW WESTROCK COFFEE COMPANY LLC
SRBK STRAWBERRY FIELDS REIT INC.
SDHC SR BANCORP INC
EVM SMITH DOUGLAS HOMES CORP
TXO EATON VANCE INSD CALIF MUN BD FD
GF MORNINGSTAR PARTNERS
GREE L.P.
HCWB THE NEW GERMANY FUND
INC.
GREENIDGE GENERATION HLDGS INC
HCW BIOLOGICS INC
Rayonier Advanced Materials Inc: 1 director
A director at Rayonier Advanced Materials Inc bought 63,291 shares at 3.948USD and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last ...
Esperion to Participate in Upcoming June Investor Conferences
Esperion to Participate in Upcoming June Investor Conferences ANN ARBOR, Mich., May 20, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of June, which can be found on our investor relations . Jefferies Global Healthcare Conference in New York on June 4, 2025, at 1:25 p.m. ET. Goldman Sachs Global Healthcare Conference in Miami on June 9, 2025, at 10:40 a.m. ET. Live webcasts can be accessed on the investor and media section of the Esperion . Access to the webcast replay w...
OPKO Health to Participate in Two Upcoming Investor Conferences
OPKO Health to Participate in Two Upcoming Investor Conferences MIAMI, May 15, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in two investor conferences over the coming weeks. H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq, May 20 in New York City. Management will hold one-on-one meetings with investors and will participate in a fireside discussion at 9:00 a.m. Eastern time. Jefferies Global Healthcare Conference, June 3-5 at the Marriott Marquis in New York City. Management will hold one-on-one meet...
Arch Capital Group Ltd: 1 director
A director at Arch Capital Group Ltd sold/sold after exercising options 99,056 shares at 94.006USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's dire...
UFP Technologies Inc: 1 director
A director at UFP Technologies Inc sold 1,473 shares at 220.123USD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
Middlefield Banc Corp. Announces 2025 Second-Quarter Cash Dividend Pay...
Middlefield Banc Corp. Announces 2025 Second-Quarter Cash Dividend Payment MIDDLEFIELD, Ohio, May 12, 2025 (GLOBE NEWSWIRE) -- Middlefield Banc Corp. (NASDAQ: MBCN) today announced that its Board of Directors declared a quarterly cash dividend of $0.21 per common share. The 2025 second-quarter dividend is payable on June 13, 2025, to shareholders of record on May 30, 2025. About Middlefield Banc Corp. Middlefield Banc Corp., headquartered in Middlefield, Ohio, is the Bank holding Company of The Middlefield Banking Company, with total assets of $1.89 billion at March 31, 2025. The Bank op...
Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Ge...
Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040 ANN ARBOR, Mich., May 12, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Micro Labs USA, Inc. and its affiliate Micro Labs Limited (together, Micro Labs). This agreement resolves the patent litigation brought by Esperion against Micro Labs in response to Micro Labs’ Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of NEXLETOL prior to the expiratio...
Esperion to Participate in H.C. Wainwright’s 3rd Annual BioConnect Inv...
Esperion to Participate in H.C. Wainwright’s 3rd Annual BioConnect Investor Conference ANN ARBOR, Mich., May 09, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, at 10 a.m. ET. The live webcast can be accessed on the investor and media section of the Esperion . Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days. Esperio...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) ANN ARBOR, Mich., May 08, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on May 7, 2025, the Company granted 15 new employees 49,300 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement material to such individual...
Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (be...
Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada – Esperion to Receive an Upfront Payment, Near-Term Milestones and Tiered Royalties on Product Sales – – Further Expands Global Access to Bempedoic Acid Products and Provides Opportunity to Bring Innovative Preventative Therapy to 2.6 million Canadians Living with Diagnosed Heart Disease – ANN ARBOR, Mich., May 08, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics (NASDAQ: ESPR) today announced it has entered into a license and distribution agreement wi...
UFP Technologies Announces Record Q1 Results
UFP Technologies Announces Record Q1 Results NEWBURYPORT, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (Nasdaq: UFPT), a designer and custom manufacturer of comprehensive solutions primarily for the medical market, today reported net income of $17.2 million or $2.21 per diluted common share outstanding for its first quarter ended March 31, 2025, compared to net income of $12.7 million or $1.64 per diluted common share outstanding for the first quarter of 2024. Net Sales for the first quarter were $148.1 million compared to 2024 first quarter sales of $105.0 million. Thro...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.